White Papers Archives - Page 4 of 5

Philippe Généreux, MD Presents Novel Research on Aortic Stenosis from egnite, Inc.’s Database at Transcatheter Cardiovascular Therapeutics Conference 2023

October 24, 2023

Led by Philippe Généreux, MD and Colleagues, Findings Presented Today at the TCT Conference. Key Findings Demonstrate Patients With Aortic Stenosis Have Substantial Untreated Mortality Risk Across All Levels of Aortic Stenosis Severity, but Aortic Valve Replacement Rates Remain Low Even for Patients With Severe Aortic Stenosis…

Using AI and Big Data to Speed Up Cardiovascular Clinical Trials

June 14, 2023

Clinical trials are necessary to ensure the safety and efficacy of new therapies, but they can be time-consuming, costly and inefficient to enroll, slowing down access to lifesaving treatment options. The future of faster clinical trials is here.

Clinical Journey for Patients with Aortic Regurgitation: A Retrospective Observational Study From a Multicenter Database

June 9, 2023

“This is one of the first artificial intelligence-driven studies providing critical insights into care patterns for patients with moderate or greater AR in the community. The urgency for digital technologies to identify AR patients earlier and novel therapies to improve outcomes for this vulnerable patient population has never been greater.”

egnite, Inc. and JenaValve Announce Strategic Partnership to Uncover Trends in Care for Patients with Aortic Regurgitation

June 9, 2023

Partnership aims to understand the care paradigm and associated outcomes for patients with aortic regurgitation. First study presented by Nick Amoroso, MD, at the TVT Structural Heart Summit in Phoenix, Arizona.

Outcomes With Guideline-Directed Medical Therapy and Cardiac Implantable Electronic Device Therapies For Patients With Heart Failure With Reduced Ejection Fraction

May 21, 2023

“Over the last five years, new therapies to treat heart failure emerged with promising improvements in survival benefit. This study represents the first time we’ve seen an assessment of ‘5-class’ guideline-directed therapy — up to 4 foundational medication classes plus ICD/CRT-D therapy — for these patients. The next big challenge